Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
93 hedge funds and large institutions have $133M invested in Kronos Bio in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 21 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
3% less funds holding
Funds holding: 96 → 93 (-3)
3.86% less ownership
Funds ownership: 68.9% → 65.04% (-3.9%)
53% less capital invested
Capital invested by funds: $282M → $133M (-$149M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.77M |
| 2 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$1.95M |
| 3 |
Two Sigma Investments
New York
|
+$1.33M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$22.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.59M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.21M |
| 5 |
CC
Casdin Capital
New York
|
-$2.08M |
KRON Hedge Fund Activity: Q2 2022 in Review
93 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q2 2022, worth a combined $133M — down 53% from $282M a quarter earlier.
Fund positioning in KRON was balanced in Q2 2022: 21 funds opened new positions, 21 closed out, 31 added to existing stakes and 20 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $2.77M. The largest seller was Capital World Investors, exiting entirely with an estimated $22.3M sold.
- 93 institutional investors held Kronos Bio (KRON) as of Q2 2022, down from 96 in Q1 2022.
- Funds reported $133M of Kronos Bio stock for Q2 2022, down 53% quarter-over-quarter.
- 21 funds opened new Kronos Bio positions in Q2 2022 and 21 closed out, a net change of 0 holders.
- The largest Kronos Bio buyer in Q2 2022 was Renaissance Technologies, an estimated $2.77M added.
- The largest Kronos Bio seller in Q2 2022 was Capital World Investors, an estimated $22.3M sold.
Based on aggregated 13F filings for Q2 2022.